

**Cognitive difference in young adult *C9orf72* repeat expansion and *GRN* mutation carriers support neurodevelopmental effects of genetic FTD**

Rubina Malik, Martina Bocchetta, Kristy Coleman, Caroline Graff, Barbara Borroni, Mario Masellis, Robert Laforce, Caroline Greaves, Lucy Russel, Rhian Convery, Arabella Bouzigues, David Cash, Markus Otto, Matthis Synofzik, James Rowe, Daniela Galimberti, Pietro Tiraboschi, Robert Bartha, Christen Shosmith, Maria Carmela Tartaglia, John C. van Swieten, Harro Seelaar, Lize C. Jiskoot, Sandro Sorbi, Chris R. Butler, Alexander Gerhard, Raquel Sanchez-Valle, Alexandre de Mendonça, Fermin Moreno, Rik Vandenberghe, Isabelle Le Ber, Johannes Levin, Florence Pasquier, Isabel Santana, Jonathan D. Rohrer, Simon Ducharme, Elizabeth Finger

Recent research suggests that genetic FTD may have neurodevelopmental consequences. Cortical and subcortical volume loss can be observed over a decade prior to disease onset (Tavares et al. 2019; Cash et al., 2018; Rohrer et al., 2015), and kindreds of *C9orf72* repeat expansion carriers have higher rates of neurodevelopmental disorders, such as autism, than familial non-carriers (Devenney et al., 2018). Here, we examine whether changes in brain function based on symptom endorsement or cognitive performance are detectable in the youngest adult FTD mutation carriers at ages near the end of the neurodevelopmental period.

Participants included 71 young adults (18-29 years), from the Genetic Frontotemporal Dementia Initiative (GENFI). Forty-nine percent of participants were mutation carriers, and 51% were non-carriers.

Significant task performance differences between carriers and non-carriers were observed for each genetic group. Male *C9orf72* expansion carriers performed worse than non-carriers on the digit symbol and color word interference tasks, and scores decreased for older male carriers with age on the block design task (all  $p < 0.05$ ). Young adult *MAPT* mutation carriers performed better than non-carriers on the letter fluency task, and their study partners reported fewer symptoms in comparison to non-carriers ( $p < 0.05$ ). In *GRN* mutation carriers, a significant interaction between carrier status and age was found on the verbal phonemic fluency task ( $p < 0.05$ ), with a trend towards better performance in young ( $< 26.05$  years) non-carriers compared to young carriers ( $p = 0.065$ ).

These findings suggest potential neurodevelopmental consequences of FTD mutations with distinct cognitive profiles that could serve to inform interventions for at-risk individuals.

**Conflicts of interest**

N/A